Clearside Biomedical completes Series A financing

February 22, 2012 at 12:36 pm Leave a comment

With an investment from the GRA Venture Fund, LLC, Clearside Biomedical has completed its Series A financing.  The company, which got its start through GRA VentureLab grants, is developing microinjection technology that uses hollow needles to target therapeutics precisely within the eye.  Based on a collaboration of researchers at Georgia Tech and Emory, the technology has the potential to provide an improved method for treating diseases that affect the back of the eye, including age-related macular degeneration.  North Carolina-based Hatteras Discovery Fund also invested $4 million in Clearside.

Read more here about the technology, its development and potential  or visit Clearside Biomedical’s website.

Entry filed under: Commercialization/VentureLab, News. Tags: .

GRA Eminent Scholar Barbara Boyan elected to NAE membership UGA launches Obesity Initiative

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Categories

Feeds


Follow

Get every new post delivered to your Inbox.